Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( <scp>AMG</scp> 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome

Abstract

Evolocumab showed encouraging safety and efficacy at 52 weeks in patients with or without dysglycaemia or MetS. Changes in glycaemic parameters did not differ between evolocumab- and placebo-treated patients within the glycaemic subgroups examined.